Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body.

The company is developing psychedelics for depression, and hopes to go public within a year of its next published results, per documents seen by BI.

Johnson & Johnson (J&J ... In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with major depressive disorder (who were ...